On December 10, 2019 PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, reported that its quarterly shareholder update will be held on December 20, 2019 at 4 P.M. EST (Press release, PharmaCyte Biotech, DEC 10, 2019, View Source [SID1234552205]). The update will include the latest information available on preparing to submit an Investigational New Drug application (IND) to the U.S. Food and Drug Administration, a review of the company’s activities during the quarter, and a Q&A period to answer any questions that shareholders may have.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

PharmaCyte requests that shareholders submit their questions for the quarterly shareholder update to the company using the email address [email protected]. Shareholders can submit questions to be addressed during the quarterly shareholder update until the close of business on December 13, 2019.

To learn more about PharmaCyte’s pancreatic cancer treatment and how it works inside the body to treat locally advanced inoperable pancreatic cancer, we encourage you to watch the company’s documentary video complete with medical animations at: View Source